161 related articles for article (PubMed ID: 31309642)
1. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
2. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
9. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
12. Low-dose tacrolimus for intractable myasthenia gravis.
Yoshikawa H; Mabuchi K; Yasukawa Y; Takamori M; Yamada M
J Clin Neurosci; 2002 Nov; 9(6):627-8. PubMed ID: 12604270
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.
Li Y; Guptill JT; Russo MA; Massey JM; Juel VC; Hobson-Webb LD; Howard JF; Chopra M; Liu W; Yi JS
Exp Neurol; 2019 Feb; 312():43-50. PubMed ID: 30472069
[TBL] [Abstract][Full Text] [Related]
14. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis.
Kawaguchi N; Yoshiyama Y; Nemoto Y; Munakata S; Fukutake T; Hattori T
Curr Med Res Opin; 2004 Aug; 20(8):1269-73. PubMed ID: 15324529
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
18. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
19. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.
Utsugisawa K; Nagane Y; Yonezawa H; Obara D; Kondoh R; Tohgi H
Muscle Nerve; 2003 Feb; 27(2):245-8. PubMed ID: 12548534
[TBL] [Abstract][Full Text] [Related]
20. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
